Keywords
Endothelial glycocalyx, lidocaine, doxycycline, cardiopulmonary bypass, anaesthesia
Endothelial glycocalyx, lidocaine, doxycycline, cardiopulmonary bypass, anaesthesia
Heart surgery is known to have harmful effects on the lining of blood vessels called the “endothelial glycocalyx” (EG)1,2. The EG is a proteoglycan coating on the luminal side of blood vessels, and is made up of a dynamic layer of polysaccharides, the composition of which is balanced under normal physiological conditions by vascular sheer forces and continued biosynthesis. Under normal conditions, the EG provides protection that helps preserve barrier function, modulate inflammation and house anticoagulant factors1. The EG is also important for normal vascular functions, including fluid and protein extravasation, coagulation/haemostasis and microvascular blood flow.
Damage to the EG results in vascular permeability, white blood cell adhesion, changes in coagulation and ultimately organ oedema and dysfunction3, making it a viable causal mechanism for these outcomes noted in post-operative cardiac patients. Supporting this, there is good evidence that the EG is rapidly shed under both inflammatory and ischaemic conditions4. Rehm and colleagues also detected a component of the EG, syndecan-1, in the plasma of patients undergoing procedures requiring local systemic ischemia, including total circulatory arrest and aortic cross clamping, which indicates that shedding has occurred5. Strategies to protect the EG are thus a viable clinical target in order to reduce adverse outcomes. Currently no measures are taken in routine practice specifically to protect the EG.
One potential strategy is the use of doxycycline, a broad-spectrum matrix metalloprotease inhibitor that reduces metalloprotease activity known to be involved in the EG shedding process4. Research trials have demonstrated that administration of doxycycline reduces EG shedding in rat mesentery vasculature4.
Alternatively, lidocaine is an amide local anaesthetic that has a broad range of applications, including as part of adenosine/lidocaine/magnesium (ALM), a cardiac protective agent. As a combination, ALM is implicated in maintaining endothelium function and vascular permeability and leads to the restoration of EG after shedding6. The primary mechanism within ALM is not yet known, however lidocaine alone has been shown to improve coagulopathies, have vasoactive effects, be a free radical scavenger and have anti-inflammatory properties and is a coronary vasodilator6. Therefore, it is suspected that lidocaine alone may be responsible for the EG-related effects of ALM. In a porcine study, an intraoperative lidocaine infusion significantly reduced the shedding of the EG in a lung transplant model7.
This research trial aims to investigate EG shedding as a cause of adverse outcomes and evaluate the use of both doxycycline and lidocaine as agents to reduce EG shedding and thereby improve early postoperative outcomes.
1. To evaluate the EG shedding in plasma and coronary sinus effluent at key time points in cardiopulmonary bypass surgery.
2. To evaluate the relative reduction in EG shedding with doxycycline and lidocaine as individual agents.
3. To correlate any reduction in EG shedding to early postoperative clinical outcomes.
We hypothesize that doxycycline and/ or lidocaine will reduce endothelial glycocalyx shedding in patients during cardiopulmonary bypass surgery.
This is protocol version 2.2.
This trial is a phase IV, single centre, prospective, unblinded, randomised, parallel-group trial consisting of three equal treatment arms (1:1:1): control group, doxycycline group, and lidocaine group. There will be 20 patients in each arm.
This is a single centre pilot trial that will take place at the Fiona Stanley Hospital (FSH; Perth, WA, Australia), which is a large academic hospital.
All patients undergoing cardiopulmonary bypass at Fiona Stanley Hospital who are ≥18 years old and provide written informed consent will be eligible to participate in the trial.
Patients will be excluded for the following reasons: patient refusal, allergy to trial drug(s), undergoing heart and lung transplant, doxycycline and/or lidocaine contraindicated in patient management, and history of chronic alcohol abuse.
Patients will be recruited via medical personnel in cardiothoracic and anaesthetic clinics and on the ward when applicable.
Written informed consent will be obtained at recruitment (Extended data8). This consent will be obtained by trained research nurses, anaesthetists or cardiothoracic surgery staff. Information sheets and consent forms will only be available in English.
Participants are able to withdraw at any stage of the trial. Samples specifically collected for the trial will be removed and disposed of if requested by the patient. Samples will not be entered to a biorepository.
Outside of initial recruitment, and the possibility of ingesting a single tablet (see Intervention section), participant responsibilities are minimal, and retention should therefore be high with recruited patients.
The primary outcome is the relative difference in the biochemical marker of EG injury, syndecan-1, at different timepoints in the intraoperative and early post-operative period.
Secondary outcomes include:
Vasopressor/inotropic requirements: requirement and agent when leaving theatre (low cut off threshold of 5mcg/minute Noradrenaline); requirement at 6 hours into ICU stay
Markers of organ function: kidney – Δ creatinine, (Including subgroup analysis for pre-existing renal failure and might need to subgroup into existing and not pre-existing renal failure, requirement of RRT); oxygen requirement – PaO2/FiO2 ratio.
Inflammation: white cell count, c-reactive protein, cytokine levels (including tumour necrosis factor α and interleukin (IL)-2, IL-4, IL-6, IL-10, and IL-17 and interferon-γ)
Bleeding: blood products usage, ROTEM, prolonged coagulopathy
Patient-based: length of ICU stay and pain severity
Unplanned return to theatre
Postoperative delirium
Arrhythmia (presence or absence of atrial fibrillation at 30 days)
We plan to recruit 60 patients randomised into three groups of 20 (see Figure 1). All recruits will be at FSH. It is difficult to do accurate power calculations as this is an exploratory pilot study, but using non-interventional human data and a published pig model2,7, with data only available for lidocaine, syndecan-1 levels peak at the end of surgery with a mean of approx. 50 pg/mL (but widely distributed), a pig model showed levels reduced by over 50% with lidocaine exposure. Therefore, if we take a mean of 50, with a standard deviation of 25 and anticipate a reduction by 50%, alpha error 0.05 and power of 80%, we require 16 in each group. Since these are very crude figures, we hope to enrol 20 patients per group to increase our chance of seeing meaningful data.
Previous experience in our department shows a recruitment rate to any clinical trial at approx. 20% of all eligible patients.
This trial aims to recruit 60 patients. Patients will be screened for eligibility in the preoperative clinic or inpatients seen on the ward. Informed consent will be sought from eligible patients. This will be undertaken by anaesthetic staff or research nursing staff. No additional visits will be required by the participants. Participants will be randomised via blocked number draw and assigned to one arm of the study. Patients will undergo randomisation in groups of three, i.e. at the time of recruitment each patient will be randomised to one of the three trial arms with the process repeating with each subsequent three patients. Randomisation will be conducted by opaque envelope method in a 1:1:1 ratio. The envelopes will be sequentially numbered, and each patient will be assigned to the next envelope. The sequencing will be performed externally to the investigators by the hospital pharmacy (clinical trials) unit.
Clinicians and researchers will not be blinded to allocations; however, laboratory staff will not be aware of the allocations and statistical analysis will be performed on the data by researchers on anonymised data blinded to the allocations. Emergency unblinding therefore will not be an issue.
Drugs will be supplied by the South Metropolitan Service Pharmacy Department. All treatments will take place in FSH perioperative department. Treatment conditions will be as follows:
1. Doxycycline group: preoperative doxycycline 200mg to be administered at least two hours before patients go to theatre; in addition, patients are to be sitting upright when taking a doxycycline tablet with appropriate amount of water.
2. Lidocaine group: perioperative lidocaine infusion (1.5 mg/kg bolus given at induction of anaesthesia followed by 2 mg/kg/hr infusion until leaving the operating theatre).
3. Control group: standard care
The doxycycline group will be administered their treatment in the ward by ward nursing staff. The lidocaine group will be administered by the attending anaesthetist using the BD Alaris PK syringe pump (CareFusion, Switzerland) using a preprogramed protocol of 1.5mg/kg bolus delivered over five minutes followed by 2mg/kg/hr. Outside of the study drugs, concomitant care will be at the discretion of the primary anaesthetist. This is highly standardised in FSH; all patients receive high dose fentanyl, propofol and vecuronium at induction, and blood pressure support with noradrenaline and glyceryl trinitrate. Dobutamine is the inotrope of choice in FSH. Anaesthesia is maintained using sevoflurane and is titrated to Bispectral Index. Patients are anticoagulated with heparin with target activated clotting time of 400 seconds or greater for the duration of cardiopulmonary bypass and reversed with a suitable dose of protamine. All patients receive 2 grams of tranexamic acid at induction.
Trial specific blood samples will be collected intra-operatively and post operation (Table 1).
Blood samples will be collected for processing of plasma and storage for batch analysis by specifically appointed trial staff in anaesthesia and ICU. All samples, with the exception of syndecan-1 will be obtained from the existing hospital computer systems as appropriate. Syndecan- 1 and cytokines associated with EG injury will be quantified by ELISA using commercially available kits. ROTEM after protamine will be performed for all patients.
All other data will be extracted from the electronic medical record including ICU records. Telephone contact will be established with the participants if required.
A Data Safety Monitoring Board (DSMB) has been set up specifically for this trial. It consists of a multidisciplinary group to review, at regular intervals, accumulating trial data, in order to monitor the progress of this clinical trial. Their role is to provide advice on safety and/or trial conduct issues by making recommendations to the investigators, on whether to continue, modify or stop this trial for safety or ethical reasons. The DSMB consists of three suitable members with no vested interest into the outcome of this trial who have relevant scientific and medical expertise.
Doxycycline and lidocaine are widely available and are used frequently in the both the community and hospital setting with a well-established therapeutic and safety profile. Furthermore, lidocaine is used often in the setting of cardiac surgery for its class 1b antiarrhythmic and analgesic properties.
Any suspected adverse effects, including allergic reactions, due to the study drugs will be reported as an adverse event and investigated appropriately.
Both the actual and potential risk to patients from both agents used in this trial is considered intermediate.
Clinicians administering treatments and taking samples will be given an education session and supervised by investigators initially.
Data analysis. Data will be analysed using GraphPad statistical software version 8.4.2 (Prism Software, San Diego, USA).
We will perform interim analysis after four patients from each group (i.e. 12 patients) and at the halfway point (30 patients) and re look at power analysis if indicated by any early signals or lack of. Patients will be randomised by block number draw whereby participants are randomly assigned to one of the three trial arms in 20 rounds of three, so as to ensure balance across conditions and effective interim analysis. We will perform per protocol and intention to treat analysis on the data. Given the nature of the clinician delivered interventions, we anticipate that very few patients will crossover or be lost to follow-up, therefore the analyses should line up closely.
The principal investigators have a strong working knowledge of medical statistics; however appropriate statistical specialist input will be sought and utilised for this study. Prior studies have shown non normal distribution of syndecan-1 level distribution between participants required logarithmic transformation to use parametric testing2. We will we therefore scrutinise the data using the D’Agostino & Pearson Omnibus test and suitable parametric or non-parametric statistical tests will be used on the data. Results will be expressed accordingly.
Continuous variables and binary data will be scrutinised using appropriate tests, i.e. chi-squared test for binary outcomes, and Student’s T-test for continuous outcomes.
Data management. Information will be stored and analysed on password protected hospital computers at FSH for 15 years. Participants will be anonymised. Demographics, type of surgery etc. and treatment arm will be recorded with the recorded results. All data will be included if possible. Any missing or excluded data will be clearly outlined and explained in resulting manuscript.
All principal investigators will have access to cleaned data sets.
The principal investigators, will permit trial-related monitoring, audits, and regulatory inspections, providing direct access to source data/documents. This may include, but not limited to, the DSMB, review by external sponsors, Human Research Ethics Committees and institutional governance review bodies.
Formal systematic auditing and monitoring will be undertaken by the authors under the supervision of the DSMB at regular time points (i.e. after 12 & 30 participants and at the end of the data collection). This study will be undertaken by experienced researchers. If there is evidence of harm at any timepoint the trial will be suspended and investigated by the DSMB and may be prematurely terminated at any timepoint. Being a pilot, the trial will not be analysed for futility at the interim stages.
The principal investigators state that the trial will be conducted in compliance with the protocol, Good Clinical Practice and the application regulatory requirements. Researchers will regularly liaise with clinicians to further ensure protocol adherence.
Data will be systematically collected by experienced researchers. Of note, there is no financial incentive (or any other form of incentive) for the results to show superiority or non-inferiority in this pilot study.
This project has been reviewed and approved by the health research ethics committee (HREC) of the South Metropolitan Health Service, Western Australia (ref RGS-1190). No atypical ethical or consent issues are associated with this pilot study. Participant Information and Consent Forms will be provided to all participants and are available as Extended data8.
Any modifications with a significant impact on the study conduct, patient safety, design, sample size will require a formal protocol amendment. Significant changes considered necessary by principal investigators will require approval from South Metropolitan HREC and relevant health authorities before being instigated. Administrative changes and minor corrections deemed necessary by the principal investigators will be documented and the HREC notified.
Patients enrolled in the trial are covered by FSH hospital indemnity. Due to the short duration of the intervention and the pharmacokinetics of the study agents, post-trial care is not predicted to deviate from standard of care but will be covered by FSH indemnity if required.
It is intended that the results of this pilot study will be published and disseminated in an international journal. A minimum time will be taken to compile results after recruitment of the final participant. Deidentified data will be accessible with the final manuscript.
The trial started on 1st May 2020 and is currently recruiting patients. The trial is anticipated to finish on the 31st January 2021.
Open Science Framework: LiDEG, https://doi.org/10.17605/OSF.IO/Y2F8C8.
This project contains the following extended data:
Open Science Framework: SPIRIT checklist for ‘Preserving the endothelial glycocalyx in patients undergoing cardiopulmonary bypass: a prospective randomised interventional pilot study of lidocaine and doxycycline (LiDEG trial)’, https://doi.org/10.17605/OSF.IO/Y2F8C8.
Data are available under the terms of the http://creativecommons.org/publicdomain/zero/1.0/ (CC0 1.0 Public domain dedication).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
No
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Blood transfusion, transplantation.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Anesthesiology.
Is the rationale for, and objectives of, the study clearly described?
Partly
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Cardiac surgery.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
References
1. Pesonen E, Passov A, Salminen US, Ilmakunnas M, et al.: Heparin Binding Protein in Adult Heart Surgery.Ann Thorac Surg. 107 (4): 1154-1159 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Inflammation, coagulation and related phenomena (including also the endothelial glycocalyx) in cardiac surgery, solid organ transplantations and sepsis.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||||
---|---|---|---|---|
1 | 2 | 3 | 4 | |
Version 1 04 Aug 20 |
read | read | read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)